+

WO2007116428A3 - Oral pharmaceutical composition containing cystine or cysteine with glutathione against oxidative stress resulting from haemodialysis - Google Patents

Oral pharmaceutical composition containing cystine or cysteine with glutathione against oxidative stress resulting from haemodialysis Download PDF

Info

Publication number
WO2007116428A3
WO2007116428A3 PCT/IT2007/000261 IT2007000261W WO2007116428A3 WO 2007116428 A3 WO2007116428 A3 WO 2007116428A3 IT 2007000261 W IT2007000261 W IT 2007000261W WO 2007116428 A3 WO2007116428 A3 WO 2007116428A3
Authority
WO
WIPO (PCT)
Prior art keywords
cysteine
haemodialysis
pharmaceutical composition
composition containing
oxidative stress
Prior art date
Application number
PCT/IT2007/000261
Other languages
French (fr)
Other versions
WO2007116428A2 (en
WO2007116428A8 (en
Inventor
Francesco Santangelo
Francesco Paolo Pilato
Original Assignee
Bio3 Res Srl
Francesco Santangelo
Francesco Paolo Pilato
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bio3 Res Srl, Francesco Santangelo, Francesco Paolo Pilato filed Critical Bio3 Res Srl
Priority to MX2008012974A priority Critical patent/MX2008012974A/en
Publication of WO2007116428A2 publication Critical patent/WO2007116428A2/en
Publication of WO2007116428A8 publication Critical patent/WO2007116428A8/en
Publication of WO2007116428A3 publication Critical patent/WO2007116428A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/06—Tripeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Urology & Nephrology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

Described herein is an oral pharmaceutical composition containing cystine or cysteine with glutathione, for the prevention and treatment of oxidative stress resulting from haemodialysis treatment in patients affected by chronic renal insufficiency.
PCT/IT2007/000261 2006-04-10 2007-04-06 Oral pharmaceutical composition containing cystine or cysteine with glutathione against oxidative stress resulting from haemodialysis WO2007116428A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
MX2008012974A MX2008012974A (en) 2006-04-10 2007-04-06 Oral pharmaceutical composition containing cystine or cysteine with glutathione against oxidative stress resulting from haemodialysis.

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IT000206A ITRM20060206A1 (en) 2006-04-10 2006-04-10 ORAL PHARMACEUTICAL COMPOSITION CONTAINING CYSTINE OR CISTEIN WITH GLUTATHYATE FOR THE PREVENTION AND TREATMENT OF OXIDATIVE STRESS FROM HEMODIALYSIS AND MEDICAL ADMINISTRATION DEVICE
ITRM2006A000206 2006-04-10

Publications (3)

Publication Number Publication Date
WO2007116428A2 WO2007116428A2 (en) 2007-10-18
WO2007116428A8 WO2007116428A8 (en) 2007-12-13
WO2007116428A3 true WO2007116428A3 (en) 2008-03-13

Family

ID=38480485

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IT2007/000261 WO2007116428A2 (en) 2006-04-10 2007-04-06 Oral pharmaceutical composition containing cystine or cysteine with glutathione against oxidative stress resulting from haemodialysis

Country Status (4)

Country Link
KR (1) KR20090024673A (en)
IT (1) ITRM20060206A1 (en)
MX (1) MX2008012974A (en)
WO (1) WO2007116428A2 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2527802B (en) * 2014-07-02 2019-10-16 Olimed Ltd An orally disintegrating tablet with differentiated absorption
FR3092491B1 (en) * 2019-02-11 2021-11-12 Bretagne Chimie Fine Non-therapeutic oral use of a composition for whitening and / or lightening the skin comprising cystine and glutathione in a cystine / glutathione ratio ranging from 1.5 to 4
EP4216939A4 (en) * 2020-09-28 2024-10-23 Georgia Tech Research Corporation USE OF CYSTIN AND ITS DERIVATIVES AS ANTITHROMBOTIC AND THROMBOLYTIC AGENTS

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0146265A2 (en) * 1983-11-15 1985-06-26 Kyowa Hakko Kogyo Co., Ltd. Process for producing a compound from its precursor using an enzymatic activity of bacterium
US5576287A (en) * 1994-04-29 1996-11-19 Wake Forest University Method for treating acute renal disease and failure
WO2000028977A1 (en) * 1998-09-29 2000-05-25 Thione International, Inc. Antioxidant gel for gingival conditions
WO2001002004A1 (en) * 1999-07-02 2001-01-11 Lee Hibahl Peritoneal dialysis solution containing antioxidant for treating renal failure
WO2005058305A1 (en) * 2003-12-19 2005-06-30 Bio 3 Research S.R.L. The use of cystine or cysteine for the prevention and treatment of oxidative stress caused by haemodialysis and of acute or chronic kidney diseases

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0146265A2 (en) * 1983-11-15 1985-06-26 Kyowa Hakko Kogyo Co., Ltd. Process for producing a compound from its precursor using an enzymatic activity of bacterium
US5576287A (en) * 1994-04-29 1996-11-19 Wake Forest University Method for treating acute renal disease and failure
WO2000028977A1 (en) * 1998-09-29 2000-05-25 Thione International, Inc. Antioxidant gel for gingival conditions
WO2001002004A1 (en) * 1999-07-02 2001-01-11 Lee Hibahl Peritoneal dialysis solution containing antioxidant for treating renal failure
WO2005058305A1 (en) * 2003-12-19 2005-06-30 Bio 3 Research S.R.L. The use of cystine or cysteine for the prevention and treatment of oxidative stress caused by haemodialysis and of acute or chronic kidney diseases

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
MOBERLY J B ET AL: "ELEVATION OF WHOLE-BLOOD GLUTATHIONE IN PERITONEAL DIALYSIS PATIENTS BY L-2-OXOTHIAZOLIDINE-4-CARBOXYLATE, A CYSTEINE PRODRUG (PROCYSTEINE)", JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, WILLIAMS AND WILKINS, BALTIMORE, MD, US, vol. 9, no. 6, June 1998 (1998-06-01), pages 1093 - 1099, XP008046078, ISSN: 1046-6673 *
SULIMAN M E ET AL: "Effects of high-dose folic acid and pyridoxine on plasma and erythrocyte sulfur amino acids in hemodialysis patients", JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY 1999 UNITED STATES, vol. 10, no. 6, 1999, pages 1287 - 1296, XP008085534, ISSN: 1046-6673 *

Also Published As

Publication number Publication date
WO2007116428A2 (en) 2007-10-18
WO2007116428A8 (en) 2007-12-13
KR20090024673A (en) 2009-03-09
ITRM20060206A1 (en) 2007-10-11
MX2008012974A (en) 2008-12-18

Similar Documents

Publication Publication Date Title
EA201100958A1 (en) PHARMACEUTICAL ORAL DOSED DOSAGE FORM BASED ON DPP IV INHIBITORS
EP2982696A3 (en) Treatment of acute lymphoblastic leukemia
IL184554A0 (en) Pharmaceutical composition for the treatment or prevention of diseases involving obesity, diabetes, metabolic syndrome, neuro-degenerative diseases and mitochondria dysfunction diseases
MY148723A (en) Use of pinolenic acid for the treatment of obesity
EA201200968A1 (en) USE OF TRANS-CLOMIPHENE FOR THE PREVENTION OR TREATMENT OF DIABETES TYPE 2 IN MEN
NZ594814A (en) Peptide that is derived from a milk protein and has an antioxidative effect and also acts as a blood adiponectin level increase promotion and/or decrease inhibition agent
ES2356883A1 (en) Compositions for the treatment of pain and/or inflamation
WO2008022974A3 (en) Anti-diabetes composition containing chicoric acid and/or one of the metabolites thereof
TW200700071A (en) Novel use
MX2010001849A (en) Cyclic depsipeptides.
WO2008046865A3 (en) Long-term feed - elderly
WO2008017752A3 (en) Eucalyptus extract, method of preparation and therapeutic uses thereof
WO2005077103A3 (en) Compositions and methods for modification and prevention of sars coronavirus infectivity
WO2009068708A8 (en) Pharmaceutical composition with prolonged release of somatostatin or an analogue thereof
WO2009144551A3 (en) Use of dronedarone or a pharmaceutically acceptable salt thereof, for the preparation of a medicament for regulating the potassium level in the blood
WO2008008882A3 (en) Glucocorticoid receptor modulator and methods of use
WO2007116428A8 (en) Oral pharmaceutical composition containing cystine or cysteine with glutathione against oxidative stress resulting from haemodialysis
EP2193789B8 (en) The application of 5-methyl-1,3-benzenediol or derivatives thereof in the preparation of medicines and functional foods for treatment or prevention of depression
EA200702336A1 (en) APPLICATION 24-NorUDK
EA200801890A1 (en) MEANS FOR THE TREATMENT OF NOISE IN THE EARS
EP1997503A3 (en) Treatment of melanoma with alpha thymosin peptides
MX2009009966A (en) Composition useful for the prevention of type 2 diabetes and its complications in pre-diabetic patients with insulin resistance.
ZA200705349B (en) Pharmaceutical composition for the treatment or prevention of diseases involving obesity, diabetes, metabolic syndrome, neuro-degenerative diseases and mitochondria dysfunction diseases
WO2008121006A8 (en) Selenium administration
EA201000738A1 (en) MEDICAL INDICATION 3- (2,2,2-TRIMETHYLGYDRAZINIUM) PROPIONATE GYDROFUMATE AND DIGITROPHOSPHATE

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 07736765

Country of ref document: EP

Kind code of ref document: A2

WWE Wipo information: entry into national phase

Ref document number: MX/a/2008/012974

Country of ref document: MX

Ref document number: 4082/KOLNP/2008

Country of ref document: IN

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 1020087027326

Country of ref document: KR

122 Ep: pct application non-entry in european phase

Ref document number: 07736765

Country of ref document: EP

Kind code of ref document: A2

点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载